Patents by Inventor Basil Pawlyk

Basil Pawlyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RPGR gene therapy for retinitis pigmentosa
    Patent number: 11045558
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: June 29, 2021
    Assignees: Massachusetts Eye & Ear Infirmary, UCL Business Ltd., The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA
    Publication number: 20200215203
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Application
    Filed: June 10, 2019
    Publication date: July 9, 2020
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • RPGR gene therapy for retinitis pigmentosa
    Patent number: 10314924
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: June 11, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, UCL Business PLC, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA
    Publication number: 20170216454
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Application
    Filed: July 17, 2015
    Publication date: August 3, 2017
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • RPGRIP1 GENE THERAPY FOR LEBER CONGENITAL AMAUROSIS
    Publication number: 20140364488
    Abstract: This invention relates to methods for treating subjects with vision loss due to advanced Leber Congenital Amaurosis (LCA), e.g., LCA6, which is due to loss-of-function mutations in the gene encoding the retinitis pigmentosa GTPase regulator interacting-protein-1 (RPGRIP1) protein.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Inventors: Basil Pawlyk, Eliot L. Berson, Tiansen Li, Michael A. Sandberg